Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Fineline Cube Jan 19, 2026
Company Deals

3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong

Fineline Cube Oct 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...

Policy / Regulatory

China’s NMPA and Denmark’s Medicines Agency Commit to Enhanced Regulatory Cooperation

Fineline Cube Oct 25, 2024

The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...

Company Deals

NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China

Fineline Cube Oct 25, 2024

NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...

Company Deals

HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy

Fineline Cube Oct 25, 2024

HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...

Company Deals

Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies

Fineline Cube Oct 24, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...

Company Drug

Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain

Fineline Cube Oct 24, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco

Fineline Cube Oct 24, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab

Fineline Cube Oct 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...

Company Drug

Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy

Fineline Cube Oct 24, 2024

Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

Fineline Cube Oct 24, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Policy / Regulatory

NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines

Fineline Cube Oct 24, 2024

The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...

Company Deals

Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004

Fineline Cube Oct 23, 2024

Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...

Company

Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials

Fineline Cube Oct 23, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

LINDIS Biotech’s Catumaxomab Receives Positive Opinion from EMA’s COMP for Malignant Ascites Treatment

Fineline Cube Oct 23, 2024

LINDIS Biotech GmbH, a German biotechnology company, has announced that the Committee for Orphan Medicinal...

Policy / Regulatory

China’s NMPA Launches Pilot Program for Phased Manufacturing of Biological Products

Fineline Cube Oct 23, 2024

The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...

Company Deals

Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development

Fineline Cube Oct 23, 2024

Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...

Company Medical Device

China Grand Pharmaceutical Receives NMPA Approval for Innovative Adjustable Thrombectomy Stent

Fineline Cube Oct 23, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has...

Company Deals Drug

Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury

Fineline Cube Oct 23, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...

Policy / Regulatory

Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines

Fineline Cube Oct 23, 2024

The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...

Company Drug

Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections

Fineline Cube Oct 23, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has...

Posts pagination

1 … 224 225 226 … 611

Recent updates

  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.